Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

S562 Incidence of Young-Onset Barrett’s Esophagus is Increasing: A Population-Based Study From a Multi-Institutional National Database
Vasireddy, Anila , Chandar, Apoorva K., Maravillas, Mart Andrew , Pérez, Jaime A. , Perneth, Sandra Algarin, Leggett, Cadman, Iyer, Prasad G. , Gaddam, Srinivas , Kamboj, Amrit K. , Leggett, Cadman L.

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S389-S390

10.14309/01.ajg.0001031616.24587.11 Get It

S457 Next Generation mt-sDNA Has the Best Balance Between the Benefit and Burden of the Age- and Interval-Recommended CRC Screening Among Stool- and Blood-Based Tests
Kisiel, John B. , Ebner, Derek W. , Fendrick, A. Mark , Estes, Chris , Vahdat, Vahab , Ozbay, A. Burak , Limburg, Paul J.

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S321-S321

10.14309/01.ajg.0001031196.77432.81 Get It

S456 Impact of Preference-Based Digital Navigation on Multi-Target Stool DNA Test Adherence in a Large Colorectal Cancer Screening Population
Greene, Mallik , Pew, Timo, Johnson, Will K., Ozbay, A. Burak , Kisiel, John B. , Fendrick, A. Mark , Johnson, Will K., Limburg, Paul J.

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S321-S321

10.14309/01.ajg.0001031192.87627.ec Get It

S426 Gap Closure Adherence to Multi-Targeted Stool DNA Test for Colorectal Cancer Screening in an Insured Cohort
Le, Quang A. , Greene, Mallik , Pew, Timo, Philp, Alisdair R. , Doré, Michaël , Johnson, Will K., Ozbay, A. Burak , Fendrick, A. Mark , Ebner, Derek W. , Kisiel, John B. , Limburg, Paul J.

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S302-S302

10.14309/01.ajg.0001031072.99009.1f Get It

S2725 The Dual Assault of COVID-19: Hepatitis and Pancreatitis
Asad, Omar, Asad, Hakeem, Balassiano, Natalie , Benchakroun, Amal, Charnvitayapong, Panida, Carolis, Tiana De, Danjolli, Klaus, Asad, Hakeem

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1894-S1894

10.14309/01.ajg.0001040268.49620.c2 Get It

S418 Use of Flavored Polyethylene Glycol and Sulfate Solution Bowel Preparation in Patients with Obesity, Diabetes, or Taking Glucagon-Like Peptide-1 Receptor Agonists
Pambianco, Daniel J., Rex, Douglas, Beckelic, Michael E., Vargas, Eric J. , Beckelic, Michael E.

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S297-S297

10.14309/01.ajg.0001031040.88351.23 Get It

S376 Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Propensity-Matched Cohort Study
Jaber, Fouad , Alsakarneh, Saqr , Faye, Adam S , Hashash, Jana G. , Bilal, Mohammad , Shaukat, Aasma

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S267-S267

10.14309/01.ajg.0001030872.34112.8a Get It

Association of Medicaid Expansion With Timely Receipt of Treatment and Survival Among Patients With HR-Negative, HER2-Positive Breast Cancer
Shi, Kewei Sylvia , Ji, Xu , Jiang, Changchuan , Ruddy, Kathryn J. , Yabroff, K. Robin , Yabroff, K Robin , Castellino, Sharon M. , Han, Xuesong

Journal of the National Comprehensive Cancer Network | October 24, 2024 | Volume: 22 | Issue: 9 | Pages: 593-599

10.6004/jnccn.2024.7041 | PMID 39447607 Get It

Background: Hormone receptor (HR)–negative, HER2-positive (also called HER2-enriched) breast cancer has no worse prognosis than other breast cancers if it is treated with HER2-targeted therapy. Medicaid expansion under the Affordable Care Act (ACA) has been shown to be associated with improved access to care and outcomes for many cancers, but its association with receipt of care for HR-negative, HER2-positive breast cancer is unknown. We examined the association of Medicaid expansion with receipt of guideline-concordant treatment, time to treatment initiation, and survival among nonelderly women newly diagnosed with HR-negative, HER2-positive breast cancer. Patients and Methods: Women aged 18 to 62 years newly diagnosed with HR-negative, HER2-positive breast cancer between 2010 and 2018 were identified from the National Cancer Database. Outcomes included receipt of stage-based guideline-concordant treatment, timely initiation of treatment (<30 days, <60 days, <90 days from diagnosis), and stage-specific 2-year overall survival. A difference-in-differences (DID) analytic approach compared outcome changes following Medicaid expansion in expansion versus nonexpansion states. Multivariable linear probability models were used to estimate treatment outcomes, and flexible parametric survival models were used to evaluate survival, adjusting for sociodemographic and clinical confounders. Results: A total of 31,401 patients were included. Medicaid expansion was associated with an increase of 0.58 percentage points (ppt; 95% CI, 0.01–1.16) in receipt of guideline-concordant treatment overall, a 2.43-ppt (95% CI, 0.68–4.18) increase in initiating guideline-concordant treatment <60 days after diagnosis, and a 1.17-ppt (95% CI, 0.02–2.32) increase in 2-year survival rate. The increase in 2-year survival associated with Medicaid expansion was most prominent for patients with stage III disease (DID, 3.81; 95% CI, 0.82–6.80). Conclusions: Medicaid expansion was associated with improved care and survival for patients with HR-negative, HER2-positive breast cancer, an aggressive cancer type for which prognosis largely depends on access to effective treatment.
Prognostic Factors in Limited-Stage Small Cell Lung Cancer
Farris, Michael K., Mix, M. , Wang, Xiaofei , Jaszewski, Brandy L., Foster, Nathan R. , Laurie, Fran, Smith, Koren, Alden, Ryan S. , Komaki, Ritsuko , Stinchcombe, Thomas E. , Bradley, Jeffrey D. , Bogart, Jeffrey A. , Jaszewski, Brandy, Bradley, Jeffrey , Farris, Michael K , Masters, Gregory A. , Razavian, Niema B , Vokes, Everett E.

JAMA Network Open | October 24, 2024 | Volume: 7 | Issue: 10 | Pages: e2440673

10.1001/jamanetworkopen.2024.40673 | PMID 39446327 Get It

Importance The impact of patient-specific, disease-related, and social factors on outcomes in limited-stage small cell lung cancer (LS-SCLC) is not well defined. A post hoc secondary analysis of such factors from the Cancer and Leukemia Group B (CALGB) 30610–Radiation Therapy Oncology Group (RTOG) 0538 trial may impact future trial design. Objective To assess the comprehensive demographic, disease-related, treatment-related, and social factors for potential associations with survival outcomes and understand whether specific subpopulations may benefit from radiotherapy (RT) dose escalation in LS-SCLC. Design, Setting, and Participants This post hoc secondary analysis of a randomized clinical trial included 638 adults with LS-SCLC treated at 186 unique treatment sites with at least 1 accrual for all patients from March 15, 2008, to December 1, 2019; 313 patients were randomized to receive RT twice daily to a dosage of 45 Gy for 3 weeks and 325 to receive RT once daily to a dosage of 70 Gy for 7 weeks. Data were locked February 28, 2022, and analyzed from November 28, 2022, to June 4, 2024. Interventions Twice-daily RT or once-daily RT. Main Outcomes and Measures Multivariable Cox proportional hazards models evaluated the association of treatment groups and other risk factors with progression-free survival (PFS) and overall survival (OS). Patient-specific factors included age, sex, and Eastern Cooperative Oncology Group performance status. Disease-related factors included tumor, nodal, and overall cancer stages. Treatment-related factors included type of chemotherapy, timing of concurrent RT, RT technique, and prophylactic cranial irradiation. Social factors included marital status and treatment center accrual volume. Results Among 507 patients (260 [51.3%] female and 247 [48.7%] male; mean [SD] age, 62.6 [7.9] years) included in the multivariate survival analysis, with a median follow-up of 4.7 (IQR, 3.7-7.1) years, female sex was associated with improved OS (hazard ratio [HR], 0.73 [95% CI, 0.58-0.91]; P = .006), while being 70 years or older was associated with decreased OS (HR, 1.50 [95% CI, 1.14-1.98]; P = .004). Neither age nor sex was associated with PFS. When compared with those with N1 disease, OS and PFS were worse in patients with N2 (HRs, 1.64 [95% CI, 1.19-2.26]; P = .002 and 1.36 [95% CI, 1.02-1.81]; P = .04, respectively) and N3 (HRs, 2.03 [95% CI, 1.40-2.93]; P &amp;lt; .001 and 1.63 [95% CI, 1.17-2.26]; P = .004) disease. Compared with stage II cancer, OS was worse for stage IIIA (HR, 1.65 [95% CI, 1.17-2.31]; P = .004) and stage IIIB (HR, 1.94 [95% CI, 1.34-2.83]; P &amp;lt; .001). Compared with high-volume accrual centers, treatment at low- or middle-volume accrual centers was associated with worse PFS (HRs, 1.94 [95% CI, 1.33-2.82; P &amp;lt; .001] and 1.44 [95% CI, 1.15-1.82; P = .002], respectively) and worse OS (HRs, 1.55 [95% CI, 1.03-2.32; P = .03] and 1.33 [95% CI, 1.04-1.70; P = .02], respectively). Conclusions and Relevance This secondary analysis of the CALGB 30610–RTOG 0538 randomized clinical trial of patients with LS-SCLC found associations between female sex or being younger than 70 years and improved overall survival and between advanced nodal stage or treatment at low- or middle-volume accrual centers and worse outcomes. These findings suggest that stratification by nodal stage, clinical stage, and age should be considered in future randomized trials. Trial Registration ClinicalTrials.gov Identifier: NCT00632853